IQVIA (IQV) Projected to Post Quarterly Earnings on Thursday

IQVIA (NYSE:IQV) is anticipated to release its Q4 2025 results before the market opens on Thursday, February 5th. Analysts expect IQVIA to post earnings of $3.40 per share and revenue of $4.2396 billion for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 5, 2026 at 9:00 AM ET.

IQVIA Stock Performance

Shares of IQV stock opened at $231.50 on Tuesday. The company has a market cap of $39.42 billion, a P/E ratio of 31.76, a PEG ratio of 2.34 and a beta of 1.36. The firm has a fifty day moving average price of $231.00 and a 200 day moving average price of $209.37. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA has a 12 month low of $134.65 and a 12 month high of $247.04.

Institutional Investors Weigh In On IQVIA

Several large investors have recently modified their holdings of IQV. Private Advisor Group LLC grew its position in IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after buying an additional 63 shares during the last quarter. E Fund Management Co. Ltd. lifted its stake in shares of IQVIA by 3.7% in the 2nd quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock worth $331,000 after acquiring an additional 74 shares during the period. Ancora Advisors LLC boosted its holdings in shares of IQVIA by 17.9% in the third quarter. Ancora Advisors LLC now owns 521 shares of the medical research company’s stock valued at $99,000 after acquiring an additional 79 shares in the last quarter. Quadrant Capital Group LLC increased its stake in shares of IQVIA by 1.7% during the third quarter. Quadrant Capital Group LLC now owns 4,732 shares of the medical research company’s stock worth $899,000 after acquiring an additional 81 shares during the period. Finally, Snowden Capital Advisors LLC raised its holdings in IQVIA by 5.3% during the second quarter. Snowden Capital Advisors LLC now owns 2,364 shares of the medical research company’s stock worth $373,000 after purchasing an additional 120 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on IQV shares. UBS Group lifted their price target on shares of IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. BMO Capital Markets began coverage on IQVIA in a research report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 target price for the company. Mizuho set a $266.00 price target on IQVIA in a research report on Friday, January 9th. Finally, JPMorgan Chase & Co. increased their price objective on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $251.06.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.